Head-to-head · WeighScore
Cielo vs Omada Health
The verdict
Cielo takes it — 69.4/100 to 55.6/100.
Cielo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cielo is a compounded-GLP-1-only telehealth platform offering semaglutide and tirzepatide with no brand-name drugs and no TRT, hair, or mental-health add-ons — a focused, single-purpose alternative to…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cielo | Omada Health |
|---|---|---|
| WeighScore | 69.4/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #121 | #435 |
| Semaglutide | $149/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $249/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #121 · C
Strengths
- Among the lowest 3-month bundle prices in compounded GLP-1 ($115/mo semaglutide)
- Single flat price across all doses simplifies titration planning
- Corporate address (St. Petersburg, FL) and customer-service phone published
Where it loses points
- No LegitScript, NABP .pharmacy, or HIPAA badge on the home page
- Pharmacy partner not named (only 'regulated FDA pharmacy partners')
- State coverage list not published — can't verify all-50-state availability
- Clinical care runs through MD Integrations, a shared third-party network used by many brands
- No brand-name Wegovy or Zepbound option
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.